Immunohistochemical Expression of CD10 in Prostatic Adenocarcinoma and its Association with Serum PSA at a Tertiary Hospital in Bangladesh

Background Prostate cancer is the fifth leading cause of cancer related death in elderly men worldwide. Major prognostic factors include Gleason grading, serum PSA and clinical stage. Gleason grading is a key component of prostate cancer diagnosis, since it indicates tumor aggressiveness and disease outcome. Also, CD10 immune expression in Prostatic Adenocarcinoma and its association with serum PSA level has a great prognostic significance and is directly related to the patient's fate. Aims and Objectives This study includes immunohistochemical expression of CD 10 in Prostatic adenocarcinoma (observed by Gleasons Grading system) and its association with serum PSA. Materials and Methods This is a cross-sectional observational study. The study population were the patients who undergone prostatic core needle biopsy or transurethral resection of the prostate and diagnosed as prostatic adenocarcinoma in the Department of Pathology at Sir Salimullah Medical College and Bangabandhu Sheikh Mujib Medical University. A total 70 cases were selected and among these 70 cases 61 cases were core needle biopsy and 9 were transurethral resection of prostate (TURP). Demographic and histopathological variables (age, grading of tumor and PSA value) were assessed and immunohistochemical expression of CD10 were observed. Statistical analysis was performed on the tabulated data by ANOVA and Chi Square test. Observation and Result Among the 70 selected cases, majority (n=18, 25.7%) of the tumors were in grade group III. In this study, intensity of CD10 expression was diffusely positive (>20%) in 47 (67.1%) cases, focal positive (5-20%) in 19 (27.1%) cases and negative (<5%) in 4 (5.7%) cases. This study found a significant association between CD10 expression and Gleason grade group. But serum PSA values did not show any significant association with CD10 expression. Conclusion In addition to Gleason grade group, the use of CD10 immune marker and serum PSA value may have significant prognostic value for categorizing high risk patients in prostatic adenocarcinoma. Overexpression of CD10 can be used to help clinician to take more rational measures for patients.